CLDX R&D Expense Growth
Celldex Therapeutics Inc · R&D Expense Growth
CLDX R&D Expense Growth
Latest reported49.86%period ending
CLDX FY R&D Growth (YoY) (0.00% → 49.86%)
Latest values, visible window
High-resolution chart · PNG
CLDX r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 49.8624% | |
| 38.5888% | |
| 43.4645% | |
| 44.7924% | |
| 40.1564% | |
| -5.0103% | |
| -35.7823% | |
| -30.9054% | |
| -6.3811% | |
| 2.5506% | |
| -4.0333% | |
| 54.8657% | |
| 42.2022% | |
| 46.1142% | |
| 17.3201% | |
| 5.6594% | |
| -0.6763% | |
| 42.4497% | |
| 2.3768% | |
| 28.4649% | |
| 1.3658% | |
| 38.4431% | |
| -31.8673% | |
| -31.8436% | |
| 100.2979% | |
| 36.8709% | |
| 38.1018% | |
| 7.5472% | |
| -11.6667% | |
| -25% | |
| -8.046% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |